COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

24,521 Articles (18,646 medRxiv, 5,875 bioRxiv)

Most recent first Previous |  Page 4: Articles 31-40  | Next

Optimization of Ventilation Therapy Prioritization Strategies among Patients with COVID-19: Lessons Learned from Real-World Data of nearly 600,000 Hospitalized Patients
Abbasi-Kangevari, M., Ghanbari, A., Malekpour, M.-R., Ghamari, S.-H., Azadnajafabad, S., Saeedi Moghaddam, S., Keykhaei, M., Haghshenas, R., Golestani, A., Rashidi, M.-M., Ghasemi, E., Rezaei, N., Jamshidi, H. R., Rezaei, N., Larijani, B.
10.1101/2022.08.04.22278438 — Posted: 2022-08-06
Inferring time-varying generation time, serial interval and incubation period distributions for COVID-19
Chen, D., Lau, Y. C., Xu, X.-K., Wang, L., Du, Z., Tsang, T. K., Wu, P., Lau, E. H. Y., Wallinga, J., Cowling, B. J., Ali, S. T.
10.1101/2022.08.05.22278461 — Posted: 2022-08-06
COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
Xu, R., Wang, L., Volkow, N. D., Davis, P. B., Berger, N. A., Kaelber, D. C.
10.1101/2022.08.04.22278450 — Posted: 2022-08-06
Finding a Needle in the Haystack: Design and Implementation of a Digital Site-less Clinical Study of Serial Rapid Antigen Testing to Identify Asymptomatic SARS-CoV-2 Infection
Soni, A., Herbert, C., Pretz, C., Stamegna, P., Filippaios, A., Shi, Q., Suvarna, T., Harman, E., Schrader, S., Nowak, C., Schramm, E., Kheterpal, V., Behar, S., Tarrant, S., Ferranto, J., Hafer, N., Robinson, M., Achenbach, C., Murphy, R., Manabe, Y. C., Barton, B., O'Connor, L., Fahey, N., Orvek, E., Lazar, P., Ayturk, D., Wong, S., Zai, A., Cashman, L., Rao, L. V., Luzuriaga, K., Lemon, S. C., Blodgett, A., Heetderks, W., Broach, J., McManus, D.
10.1101/2022.08.04.22278274 — Posted: 2022-08-05
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
Graham, C., Lechmere, T., Rehman, A., Seow, J., Kurshan, A., Huettner, I., Maguire, T. J. A., Tam, J., Cox, D., Ward, C., Racz, M., Waters, A., Mant, C., Malim, M. H., Fox, J., Doores, K. J.
10.1101/2022.08.04.22278160 — Posted: 2022-08-05
Human endogenous retrovirus-R envelope is a host restriction factor against severe acute respiratory syndrome-coronavirus-2
Gupta, N., Ansari, S., Verma, R., Singh, O. N., Yadav, M. K., Binayke, A., Jakhar, K., Mani, S., Awasti, A., Shalimar, , Nayak, B., Ranjith-Kumar, C., Surjit, M.
10.1101/2022.08.05.502940 — Posted: 2022-08-05
Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
Tamura, T., Yamasoba, D., Oda, Y., Ito, J., Kamasaki, T., Nao, N., Hashimoto, R., Fujioka, Y., Suzuki, R., Wang, L., Ito, H., Kimura, I., Yokota, I., Kishimoto, M., Tsuda, M., Sawa, H., Yoshimatsu, K., Ohba, Y., Yamamoto, Y., Nagamoto, T., Kanamune, J., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Matsuno, K., Takayama, K., Tanaka, S., Sato, K., Fukuhara, T.
10.1101/2022.08.05.502758 — Posted: 2022-08-05
SARS-CoV-2 entry route impacts a range of downstream viral and cellular processes
Qu, B., Miskey, C., Goemer, A., Potmus, D., Nocke, M., Kleinert, R. D. V., Itotia, T. K., Valder, L., Brueckmann, J., Hoeck, S., Hastert, F. D., von Rhein, C., Schuermann, C., Ebenig, A., Widera, M., Ciesek, S., Pfaender, S., Ivics, Z., Schnierle, B. S., Tarr, A. W., Goffinet, C., Muehlebach, M. D., Todt, D., Brown, R. J. P.
10.1101/2022.08.05.502936 — Posted: 2022-08-05
mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5
Andreano, E., Paciello, I., Pierleoni, G., Maccari, G., Antonelli, G., Abbiento, V., Pileri, P., Benincasa, L., Giglioli, G., Piccini, G., De Santi, C., Sala, C., Medini, D., Montomoli, E., Maes, P., Rappuoli, R.
10.1101/2022.08.04.502828 — Posted: 2022-08-05
A specific anti-IFITM2 antibody bars the way to SARS-CoV-2 entry into host cells.
Basile, A., Zannella, C., De Marco, M., Franci, G., Galdiero, M., Sanna, G., Manzin, A., Chetta, M., Turco, M. C., Rosati, A., Marzullo, L.
10.1101/2022.08.04.502768 — Posted: 2022-08-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).